Fujimoto Naohiro
   Department   School of Medicine  Urology, Clinical Medical Sciences
   Position  
Article types 不明
Language English
Peer review Non peer reviewed
Title Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.
Journal Formal name:Clinical genitourinary cancer
Abbreviation:Clin Genitourin Cancer
ISSN code:19380682/15587673
Domestic / ForeginForegin
Volume, Issue, Page 17(3),e387-e393頁
Author and coauthor Shiota Masaki, Fujimoto Naohiro, Tsukahara Shigehiro, Ushijima Miho, Takeuchi Ario, Kashiwagi Eiji, Inokuchi Junichi, Tatsugami Katsunori, Uchiumi Takeshi, Eto Masatoshi
Publication date 2019/06
Summary INTRODUCTION:Testosterone suppression in serum during androgen deprivation therapy (ADT) can affect the oncologic outcome of ADT. Although genetic variants in sex hormone-binding globulin (SHBG) were reported to be correlated with serum testosterone level, the association with serum testosterone during ADT remains unclear. Therefore, this study investigated the impact of a missense polymorphism in the SHBG gene among men treated with primary ADT for metastatic prostate cancer.PATIENTS AND METHODS:This study included 104 Japanese men with metastatic prostate cancer. The association of SHBG gene polymorphism (rs6259, D356N) with clinicopathologic parameters including serum testosterone levels during ADT, as well as prognosis, including progression-free survival and overall survival, was examined.RESULTS:The serum testosterone levels during ADT were comparable between men carrying the homozygous wild-type (GG) and heterozygous/homozygous variant (GA/AA) in the SHBG gene. When adjusted for age, Gleason score, initial prostate-specific antigen, and clinical T-stage, the heterozygous/homozygous variant (GA/AA) in the SHBG gene was associated with a higher risk of progression (hazard ratio, 2.20; 95% confidence interval, 1.10-4.18; P = .027) and any-cause death (hazard ratio, 3.21; 95% confidence interval, 1.31-7.35; P = .012).CONCLUSIONS:This study suggested genetic variation in SHBG (rs6259) might be an independent prognostic biomarker among men treated with primary ADT for metastatic prostate cancer.
DOI 10.1016/j.clgc.2019.03.021
PMID 31036465